Caris Life Sciences, a prominent AI-driven TechBio firm and leader in precision medicine, has announced a strategic partnership with MiBA, an innovative healthcare technology company. This collaboration aims to enhance physician education and insights, thereby accelerating research and personalizing treatment plans. The partnership is designed to improve patient care and advance precision medicine by enhancing oncologists' experiences with Next Generation Sequencing (NGS) testing and facilitating clinical research through operational improvements, BioPharma clinical trials, and the identification of real-world data projects.
David Spetzler, MS, PhD, MBA, President of Caris, stated, “MiBA aligns with our dedication to innovation and enhancing patient outcomes. By merging data insights with provider education, we can guide physicians toward the most suitable molecular testing for their patients across various cancer types.”
The integration of MiBA’s technology with Caris’ extensive multimodal database will offer precise, personalized treatment options for cancer patients. MiBA’s targeted, data-driven alerts will educate oncologists about patients who qualify for comprehensive DNA and RNA profiling, including Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) testing, based on clinical guidelines.
Jason Baroff, Managing Partner at MiBA, expressed pride in partnering with Caris Life Sciences to maximize the potential of precision oncology. Mark Moch, another Managing Partner at MiBA, added that the combination of MiBA’s real-world insights engine with Caris’ advanced molecular capabilities will enhance decision-making within the oncology ecosystem, making it smarter, faster, and more collaborative.
Furthermore, MiBA plans to launch an Oncology Insights Program (OIP) in collaboration with the National Community Oncology Dispensing Association (NCODA). This initiative will provide significant provider engagement programs, education, training, and actionable insights to advance Caris’ real-world applications of molecular profiling in clinical settings.
This announcement precedes Caris’ participation in the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025, in Chicago, as well as MiBA’s and Caris’ presence at the Community Oncology Alliance (COA) Annual Conference on April 29-30 in Orlando. Both companies will showcase their ongoing efforts to foster innovation in cancer care and the benefits of data-driven partnerships.
About Caris Life Sciences
Caris Life Sciences® is a leading AI-driven TechBio company and pioneer in precision medicine, dedicated to developing and delivering innovative solutions that transform healthcare and enhance human well-being. Through comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, and the use of advanced AI and machine learning algorithms, Caris has established a large-scale multimodal database and computing capability to analyze the molecular complexities of diseases. This integration of sequencing technology, big data, and AI enables the delivery of next-generation precision medicine tools for early detection, diagnosis, monitoring, therapy selection, and drug development.
Founded with the vision of realizing the potential of precision medicine to improve human health, Caris values its employees as highly as its patients. The company is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland. Caris and its distribution partners provide services in the U.S. and various international markets. For more information, visit CarisLifeSciences.com.
About Meaningful Insights Biotech Analytics (MiBA)
MiBA is a healthcare AI technology company focused on bridging the gap between physicians, patients, and industry partners. The technology and data insights generated by MiBA aim to support pharmaceutical companies, research organizations, payers, biotech firms, health systems, and providers in enhancing the quality of patient care.
